2026-10-25
Akso Health clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,630 −6.36%
S&P 7,354 −4.36%
GOLD $4,075 −0.93%
BTC $76,040 +0.13%
VIX 26.62 −5.54%
latest tape · as of 12:04 UTC
The Screen · Healthcare · Medical Distribution
Akso Health Group
AHG · Nasdaq · USD · Market cap $1.1B · 27 employees
Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People's Republic of China.
Not yet scored1.30 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 12:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.30 USD at the 5 Nov 2026 close
- Our regime readAccumulation, as of 5 Nov 2026
- Ethical screenNot yet scored
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: range not available (screen dated 2026-11-05).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price1.30 USD
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Accumulation1.26+2.8% to today ✓Markup gives way to Accumulation
2026-10-11Read Markup1.21+7.0% to today ✓Markdown gives way to Markup after a 59% rise in 9 days
2026-10-02Read Markdown0.76+70.4% to today Distribution gives way to Markdown after a 42% slide in 6 weeks
2026-08-21Read Distribution1.30-0.4% to today ✓Markdown gives way to Distribution with volume flow in agreement
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Akso Health Group holds its Accumulation at $1.30. The statistical read favours the sellers, held for 22 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 22 days |
| Price at the screen | $1.30 |
| Valuation | N/A trailing · N/A forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | -1.58 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.20% | Below 33% | Interest-bearing debt is just 0.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 0.77% | Below 49% | Money owed to the company is 0.8% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Akso Health clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Akso Health clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
The Business, in Plain Words| EPS, trailing | -0.03 |
| Revenue growth | -12.9%revenue is shrinking |
| Profit margin | -135.0%currently unprofitable |
| Return on equity | -9.8%not currently earning a positive return on equity |
| FCF yield | -31.61% |
| Debt to equity | 1.31a meaningful debt load worth watching |
| Current ratio | 21.77comfortably covers its short-term bills |
| Beta | -1.58barely tracks the market's swings |
| Short interest, float | 0.00% |
| 52-week range | 0.68 - 2.50 |
| Market cap | $1.1B |
| Employees | 27 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to China and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAHG trades on Nasdaq (the company is based in China). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-01
Accumulation · changed $1.26
+3.3% Entry 11
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-10-25
Markup $1.22
+0.8% Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-10-11
Markup · changed $1.21
+59.2% Entry 9
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 59.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-10-02
Markdown · changed $0.76
+1.3% Entry 8
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-09-21
Distribution $0.75
-42.3% Entry 7
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 42.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-08-21
Distribution · changed $1.30
-13.9% Entry 6
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-07-20
Markdown $1.51
+12.7% Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 12.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-07-18
Markdown $1.34
+0.0% Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-07-16
Markdown $1.34
+0.0% Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 35%.
2026-07-03
Markdown $1.34
+0.0% Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Akso Health Group (AHG) Stock May Look Pricey Against Its Book Value Yahoo Finance · 21d ago
- Akso Health Group (AHG) Is Up 8.2% After Auditor Flags Going Concern Risk Despite Narrower Losses Simply Wall St. · 31 Jul 2026
- Akso Health Group (AHG) Is Up 8.2% After Auditor Flags Going Concern Risk Despite Narrower Losses Yahoo Finance · 31 Jul 2026
- AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology Yahoo Finance · 27 Apr 2026
- Akso Health Group Announces Launch of Exploratory Global Patient Support Initiative Yahoo Finance · 3 Feb 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
ACHAccendra Health Inc
FOCLFocalTherics ADR
HSICHenry Schein
YI111 Inc ADR
COSMCosmos Health Inc
CAHCardinal Health
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $1.98 | -29.8% | · | $702 | -29.8% |
| 2 months | $2.29 | -39.3% | · | $607 | -39.3% |
| 3 months | $2.20 | -36.8% | · | $632 | -36.8% |
| 6 months | $1.40 | -1.1% | · | $989 | -1.1% |
| 1 year | $1.36 | +2.2% | · | $1,022 | +2.2% |
| 2 years | $0.82 | +69.5% | · | $1,695 | +69.5% |
| 3 years | $0.34 | +302.9% | · | $4,029 | +302.9% |
| 5 years | $1.61 | -13.7% | · | $863 | -13.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AHG does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.